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doi:10.1016/j.jmii.2011.12.011Background and Purpose: Some studies have reported that the risk factors for neurosyphilis in
patients with human immunodeficiency virus (HIV) and syphilis co-infection, include CD4 cell
counts 350 cells/mL and rapid plasma reagin (RPR) titer 1:32. However, neurosyphils can
develop even in patients with CD4 cell counts >350 cells/mL or RPR titer <1:32. In this study,
we evaluated the outcome of syphilis to treatment in HIV-infected patients, and analysed the
predictors of neurosyphilis in this population.
Methods: We retrospectively reviewed medical records of HIV-infected patients with syphilis
who visited the China Medical University Hospital between January 2000 and December
2009. Neurosyphilis was defined by white blood cell (WBC) counts >20 cells/mL in the cerebro-
spinal fluid (CSF) sample or elevated Venereal Disease Research Laboratory (VDRL) titers of the
CSF samples. Treatment failure was defined as less than 4-fold decrease in the serum RPR titer
at or beyond 12 months post-treatment in case of early syphilis, and, at or beyond 24 months in
case of late syphilis.
Results: One hundred and twenty-one HIV-infected patients (average age, 32 years) with syph-
ilis were included in this study. Of 63 patients who had follow-up of serologic responses, 30
(47.6%) failed to respond to treatment. CD4 cell counts 200 cells/mL was the indicator for
treatment failure (PZ .029). Lumbar puncture was performed in 65 patients, and 14 patients
were diagnosed with neurosyphilis. At the time of lumbar puncture, 31 and 19 of the 65
patients showed CD4 cell counts of >350 cells/mL and RPR of <1:32, respectively. An HIV viral
load (VL) 10000 copies/mL was found to be associated with the development of neurosyphilis
(PZ .016).al University Hospital, No. 2, Yude Rd., North District, Taichung 404, Taiwan.
.com.tw (M.-W. Ho).
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338 Y.-J. Wang et al.Conclusion: In HIV-infected patients with syphilis, RPR titer should be evaluated more
frequently when CD4 count 200 cell/mL is associated with treatment failure. Lumbar punc-
ture for the diagnosis of neurosyphilis should be considered in patients with HIV and syphilis
co-infection, even in patients with CD4 cell counts >350 cells/mL, and particularly when the
HIV VL 10000 copies/mL.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Syphilis, caused by Treponema pallidum, is a major health
problem. This disease can mimic various infectious diseases
and shows protean clinical manifestations, including genital
ulcers, rashes, lymphadenopathy, and severe cardiovas-
cular and neurologic symptoms such as paralysis and
formation of gumma.1 Although the incidence of syphilis
decreased dramatically after the introduction of penicillin,
it has recently increased after the advent of human
immunodeficiency virus (HIV) infections.2
T. pallidum invades the central nervous system (CNS)
early during the course of the infection; the infection may
be asymptomatic or show variable expressions, ranging
from headache and oculopathy to serious conditions such as
cerebrovascular events and tabes dorsalis. HIV infection
appears to affect the neurological involvement in syphilis
and increases the risk of neurosyphilis.3e5 The use of
lumbar puncture in HIV-seropositive patients with syphilis
for neurosyphilis survey is a matter of debate among clini-
cians. Centers for Disease Control and Prevention (CDC)
recommend the criteria for the use of lumbar puncture (LP)
for diagnosing syphilis in HIV-infected patients as follows:
neurologic or ocular signs or symptoms, active tertiary
syphilis, and treatment failure.6,7 Some previous studies in
HIV-infected patients also observed risk factors of neuro-
syphilis, including CD4 cell count 350 cells/mL and rapid
plasma reagin (RPR) titer 1:32.8e10 However, neuro-
syphilis develops even in patients who have CD4 cell counts
> 350 cells/mL or RPR titer <1:32.
This retrospective study aimed to describe the clinical
and laboratory features of syphilis in HIV-infected patients.
In order to investigate the occurrence of neurosyphilis in
patients with CD4 cell counts >350 cells/mL or RPR titer
<1:32, we assessed factors that were associated with
neurosyphilis in these patients.Materials and methods
Subjects
In this study, we included patients diagnosed with HIV
infection and syphilis between January 2000 and December
2009 at China Medical University Hospital (CMUH),
a teaching hospital in mid-Taiwan. The patient’s charts
were reviewed to collect data for variables such as sex,
age, status of diagnosis of syphilis, comorbidity, syphilis
stage, cutaneous manifestations, treatment plan, history of
sexually transmitted diseases, serum RPR titer, and serumtiter for Treponema pallidum hemagglutination (TPHA). We
also reviewed neurological symptoms (photophobia, cranial
nerve abnormalities, neuropsychiatric abnormalities, focal
neurologic deficits), and cerebrospinal fluid (CSF) charac-
teristics (white blood cell (WBC) count, red blood cell (RBC)
count, percentage of monocyte, protein levels, and glucose
levels), age of the patient at the time of HIV infection, HIV
transmission route, sexual behavior, CD4 cell counts, viral
load (VL) of HIV, HIV stage, receipt of highly active anti-
retroviral therapy (HAART), opportunistic infection (OI),
and HIV-associated malignancies.
Patients with early syphilis received at least one dose of
weekly intramuscular (IM) injection of 2.4 million units of
benzathine penicillin G (BPG), those with late syphilis
received three weekly IM injections of 2.4 million units
BPG, and those with neurosyphilis received intravenous (IV)
aqueous crystalline penicillin G, 18—24 million units daily,
for 10e14 days followed by three weekly IM injections of
2.4 million units BPG.6,7 Whether to perform the lumbar
puncture in patients with syphilis was decided by the
treating physicians.
Definitions
The diagnosis and stages of syphilis were based on the Case
Definitions for Public Health Surveillance.11 Treatment
failure was defined as less than 4-fold decrease in the
serum RPR titer at or beyond 12 months post-treatment in
case of early syphilis, and, at or beyond 24 months in case
of late syphilis.6,7 Early syphilis included primary,
secondary, and early latent syphilis. Late syphilis included
late latent and syphilis of unknown duration. Neurosyphilis
was defined as CSF WBC count >20 cells/mL or elevated
Venereal Disease Research Laboratory (VDRL) titers of the
CSF samples.6,11e13 For RPR titer, TPHA titer, CD4 cell
counts, and HIV VL, only data collected within 90 days
before or after the lumbar puncture were used. HAART was
defined as concomitant use of 3 antiretroviral drugs. To
evaluate the effect of HAART, the HAART-positive group
included patients who had HAART for a duration of 6
months or more before the diagnosis of syphilis. The clinical
categories for HIV infection was based on 1993 revised
classification system.14 Cases were excluded if the CNS
infections were not caused by syphilis or if they had
concurrent CNS infections.
Laboratory methods
We used BDMacro-Vue RPR Card Tests, 18 mm Circle
Qualitative and Quantitative, (Becton Dickinson, U.S.,
Syphilis and HIV infection 339Puerto Rico) to determine serum RPR, and, FTI-SERODIA
-TPPA (Fujirebio Inc., Taiwan) to determine serum TPHA.
The CSF VDRL test was performed by using BD VDRL Antigen
(Becton Dickinson, U.S.A.). CD4 and CD8 cell counts were
performed using Cytomic FC500 system (Beckman Coulter,
Miami, USA). HIV VL was determined using the system of
COBAS AmpliPrep/COBAS HIV-1 (v1.0, Roche, Switzerland).
Statistical analysis
Continuous variables were analysed using the student’s
t test. Categorical data were analysed by the chi-square
test. Multivariable analysis was performed with logistic
regression. A 2-tailed P value < 0.05 was considered statis-
tically significant. All the statistical calculations were per-
formed using the Statistical Package for the Social Sciences
(SPSS) for Windows (Version 12.0; Chicago, IL, USA).
Results
Between January 2000 and December 2009, a total of 157
HIV-infected patients were confirmed to have syphilis.
Thirty-six patients were excluded from the study, of which
75% were MSM and 22.2% presented with early syphilis. The
causes for exclusion were as follows: CD4 cell counts not
obtained within 90 days of lumbar puncture (nZ 25), no
record of RPR titers (nZ 5), incomplete record of CSF data
(nZ 2), and tuberculosis meningitis (nZ 1), toxoplasma
brain abscess (nZ 1), and cryptococcal meningitis (nZ 2).
Among the remaining 121 patients, the mean age was 32
years (standard deviation [SD], 9.72). Among the 121Table 1 Demographic and clinical characteristics of patients w
Characteristics Total (nZ 121)
Age (mean, y) 32.0
Previous history of syphilis (%) 15.7
Early syphilis (%) 40.5
RPR titer 1:32 (%) 66.1
Risks for HIV infection (%)
MSM 75.2
Heterosexual 19.0
IVDA 5.8
Category C of HIV infection 52.9
OI (%) 12.4
HAART (%) 30.6
HIV VL 10000 copies/mL (%) 60.5
CD4 350 cells/mL (%) 50.4
Symptoms (%)
Asymptomatic 42.1
Fever 9.9
Rash 33.9
Genital ulcer 5.0
Lymphadenitis 2.5
Headache 10.7
Conscious change 5.0
Paresis 1.7
Note. LP, lumbar puncture; RPR, rapid plasma reagin; MSM, men who h
infection; HAART, highly active anti-retroviral therapy; HIV, human impatients, 49 (40.5%) presented with early syphilis: 4, 44,
and 1 patient presented with primary, secondary, and early
latent syphilis respectively. The most common route for HIV
transmission was male homosexual contact, which
accounted for 91 cases of syphilis (75.2%). Thirty-seven
patients (30.6%) had taken antiretroviral therapy for more
than 6 months before diagnosis of syphilis. Fourteen
patients were diagnosed with neurosyphilis according to
the criteria of positive results in VDRL for CSF (nZ 7) or CSF
WBC counts >20 cells/mL(nZ 7). Two of 14 patients were
asymptomatic, the others had symptoms of fever (nZ 1),
rash (nZ 5), headache (nZ 2), conscious change (nZ 3),
and paresis (nZ 2). In 7 patients who had positive results of
VDRL of the CSF samples, none of them had neurologic
symptoms. Except higher percentage of a history of
previous syphilis and clinical presentations in LP group
(23.1% vs. 7.1%), there was no significant difference
between the two groups (Table 1).
Three patients received non-penicillin treatment due to
allergy; one patient with early syphilis received tetracy-
cline and had treatment failure, the other two patients
with late syphilis, who received ceftriaxone and doxycy-
cline, had treatment success.
Follow-up serological data were not available for 58
patients; hence, these patients were excluded from the
analysis of treatment outcome. Between those with follow-
up and those without follow-up, there were no statistically
significant differences in mean age (32.0 vs. 31.9 years),
and the percentage of men who have sex with men (MSM)
(74.6% vs. 62.1 %), previous syphilis (11.1% vs. 15.5%), OI
(12.7% vs.10.3%), early syphilis (44.4% vs.29.3%), CD4 cell
count 200 cells/mL (28.6% vs. 20.7%), RPR 1:32 (64.5% vs.ith HIV and syphilis infections
LP (nZ 65) No LP (nZ 56) P value
32.4 31.6 0.657
23.1 7.1 0.001
38.5 42.9 0.75
69.8 61.8 0.129
75.4 75.0 0.961
20.0 17.9 0.765
4.6 7.1 0.553
60.0 44.6 0.337
15.4 8.9 0.283
33.9 26.8 0.401
56.3 65.5 0.306
52.3 48.2 0.653
29.2 57.1 0.002
16.9 1.8 0.005
30.8 37.5 0.435
4.6 5.4 0.851
1.5 3.6 0.473
20.0 0 0.0
9.2 0 0.02
3.1 0 0.183
ave sex with men; IVDA, intravenous drug abuse; OI, opportunistic
munodeficiency virus; VL, viral load.
Table 2 Factors influencing the treatment outcome of syphilis in 63 HIV-infected patients
Factors Univariate Multivariate
Treatment
success (nZ 33)
Treatment
failure (nZ 30)
P value Odds
Ratio
95% Confidence
Interval
P value
Previous history of syphilis (%) 12.1 10.0 0.563 1.35 0.18e10.00 0.767
Early Syphilis (%) 51.5 36.7 0.236
RPR titer 1:32 (%) 69.7 58.6 0.363
TPHA titer 1:10240 (%) 36.4 40.0 0.961
MSM (%) 75.8 73.3 0.825 1.19 0.34e4.18 0.785
OI (%) 12.1 13.3 0.885
HAART (%) 21.2 33.3 0.279 2.58 0.74e9.04 0.138
HIV VL 10000 copies/mL (%) 66.7 51.7 0.231
CD4 count 200 cells/mL (%) 18.2 40.0 0.056 4.00 1.15e13.95 0.029
Note. RPR, rapid plasma reagin; TPHA, Treponema pallidum hemagglutination; MSM, men who have sex with men; OI, opportunistic
infection; HAART, highly active anti-retroviral therapy; LP, lumbar puncture; HIV, human immunodeficiency virus; VL, viral load.
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Among 63 patients who had follow-up, 30 patients (47.6%)
showed treatment failure; CD4 cell count 200 cells/mL, at
the time of syphilis, was a predictor of treatment failure
(odds ratio [OR], 4.0; 95% confidence interval [CI],
1.2e14.0; PZ .029). No obvious associations were noted
between treatment failure and syphilis stage, HIV VL,
antiretroviral therapy, and opportunistic infections
(Table 2). Among 24 patients who had early syphilis, but
without neurosyphilis, 9 patients received1 dose IM injec-
tion of BPG and 15 patients received three dose weekly IM
injection of BPG. The rate of treatment failure was 44.4%
and 33.3%, respectively.
Of the 65 patients in whom lumbar puncture was per-
formed, 31 (47.7%) had CD4 cell count of >350 cells/mL,
and 19 (29.2%) had serum RPR titers of <1:32. Among the
patients with CD4 cell count of >350 cells/mL, 7 (22.6%)
were diagnosed with neurosyphilis, 4 showed positive VDRL
of the CSF samples and 5 showed CSF WBC counts
>20 cells/mL. In patients with CD4 cell count of >350 cells/
mL, the predictor of developing neurosyphilis was HIV VL
10000 copies/mL (85.7% vs. 29.2%, OR, 35.27; 95% CI,
1.95e638.43; PZ .016). Between the subgroups of patients
with and without neurosyphilis, there were no statistically
significant differences in the rate of early syphilis (57.1% vs.
45.8%) , RPR titer 1:32 (71.4.5% vs. 66.7%) , previousTable 3 Risk factors of neurosyphilis when serum CD4 count w
Risk factors Univariate
Neurosyphilis
(nZ 7)
Non-neurosy
(nZ 24)
Previous history of syphilis (%) 42.9 29.1
Early Syphilis (%) 57.1 45.8
RPR 1:32 (%) 71.4 66.7
TPHA 1:10240 (%) 71.4 50.0
OI (%) 0.0 4.1
HAART (%) 28.6 58.3
HIV VL 10000 copies/mL (%) 85.7 29.2
Note. LP, lumbar puncture; RPR, rapid plasma reagin; TPHA, Treponem
highly active anti-retroviral therapy; HIV, human immunodeficiency vsyphilis (42.9% vs. 29.2%), and serum TPHA of 1:10240
(71.4% vs. 50.0%) (Table 3).
In patients with serum RPR titer of <1:32, all 19 patients
were presented with late syphilis. Four (21.1%) of the 19
patients were diagnosed with neurosyphilis, 1 patient had
a positive VDRL titer of the CSF sample and 3 showed CSF
WBC counts >20 cells/mL. In patients with serum RPR titer
of <1:32, the proportion of HIV VL of 10000 copies/mL in
patients with and without neurosyphilis was 100.0% and
57.1%, respectively (PZ .086), and that of CD4 cell count
of 350 cells/mL was 50.0% and 15.0%, respectively. There
were no statistically significant differences in the rate of
previous history of syphilis, OI, and HAART (Table 4).Discussion
Syphilis, a common sexually transmitted disease, may occur
as a co-infection in HIV-seropositive patients. Syphilis can
facilitate HIV transmission, and HIV can influence the clin-
ical features and treatment outcome of syphilis. Since the
immunodeficiency is associated with a high risk of treat-
ment failure of syphilis, especially if neurosyphils was
missed, prompt diagnosis in patients with neurosyphilis is
extremely important.15e20 In the analysis of treatment
outcome, CD4 cell count of 200 cells/mL was observed toas >350 cells/mL
Multivariate
philis P value Odds
Ratio
95% Confidence
Interval
P value
0.495
0.598 0.99 0.04e24.21 0.993
0.813 0.31 0.01e10.00 0.508
0.316 11.59 0.59e227.12 0.107
0.583
0.827
0.008 35.27 1.95e638.43 0.016
a pallidum hemagglutination; OI, opportunistic infection; HAART,
irus; VL, viral load.
Table 4 Risk factors of neurosyphilis when serum RPR titer was <1:32
Risk factors Neurosyphilis (nZ 4) Non-Neurosyphilis (nZ 15) P value
Previous history of syphilis (%) 0.0 33.3 0.245
TPHA 1:10240 (%) 0.0 21.4 0.245
OI (%) 0.0 20.0 0.33
HAART (%) 0.0 20.0 0.33
HIV VL 10000 copies/mL (%) 0.0 57.1 0.086
CD4 count 350 cell/mL (%) 50.0 15.0 0.906
Note. LP, lumbar puncture; RPR, rapid plasma reagin; TPHA, Treponema pallidum hemagglutination; OI, opportunistic infection; HAART,
highly active anti-retroviral therapy; HIV, human immunodeficiency virus; VL, viral load.
Syphilis and HIV infection 341be associated with treatment failure. This finding is similar
to the observation by Ghanem et al.21 Perhaps this is
because of the immunodeficiency state induced by HIV may
reduce the immunologic response to treponemal infection.
Lower CD4 cell count that is associated with more severe
degree of immunosuppression may increase the risk of
treatment failure in HIV-infected patients who receive
penicillin treatment according to the guidelines.
Although some studies have shown that CD4 cell count
350 cells/mL and RPR titer1:32 are associated with
increased risk of neurosyphilis in HIV-infected patients with
syphilis, neurosyphilis develops even in patients without
these characteristics. In the group of patients with CD4 cell
count >350 cells/mL, 7 of 31 patients were diagnosed with
syphilis and HIV VL 10000 copies/mL was found to be
associated with neurosyphilis (PZ .016). In the setting of
RPR titer of <1:32, there was a trend between HIV VL
10000 copies/mL and neurosyphilis, but without achieving
statistical significance. Marra et al.8 suggested that HIV-1
RNA level of >500 copies/mL is associated with neuro-
syphilis. Concurrent HIV infection may alter the natural
history of syphilis by increasing the propensity of the
disease to progress to neurosyphilis.5 The explanations for
the finding that HIV VL influences the progression to neu-
rosyphilis are unclear and needs to be explored in
prospective studies of a large sample size.
The limitations of our study were as follows: First, this
was a retrospective study that was performed by review of
medical records; therefore, incomplete records may have
resulted in bias. Second, only 1 woman was included in this
study; this factor might be related to male-predominance
in the HIV-infected population in Taiwan (91.75%).22 As
a result, insufficient data were available for analysis for the
female population. Third, only 63(52.07%) of the 121
patients had regular follow up of serologic responses, which
may have led to a less accurate assessment of the prognosis
of the infection. The poor compliance may have influenced
patients’ acceptance of lumbar puncture, and treatment
failure maybe the result of undetected neurosyphilis.
Fourth, the small numbers of the study participants limited
further analysis to be performed.
In conclusion, patients with CD4 cell count of
200 cells/mL were at higher risk for treatment failure of
syphilis, and close follow-up is needed. Diagnosis of neu-
rosyphilis should be considered in HIV-infected patients
with syphilis, even in patients with CD4 cell counts
>350 cells/mL. HIV VL of 10000 copies/mL was associated
with neurosyphilis in this population, and lumbar puncture
should be performed.Acknowledgments
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